As evidenced by both preclinical and clinical studies, interventions that address insulin resistance, such as GLP-1 receptor agonists, metformin, intermittent energy restriction, or fasting-mimicking agents, might target and mitigate neurodegeneration. This evidence concerns the gene GLP1R and Insulin resistance.